Multifunctional Liposomes Targeting Amyloid ‐β Oligomers for Early Diagnosis and Therapy of Alzheimer's Disease

Early detection and treatment of Alzheimer's disease (AD) are achieved through a novel liposome-based platform. In relevantCaenorhabditis elegans AD models, biocompatible cyclicd,l- α-peptide (CP-2) conjugated liposomes (CP-2-LPs) enhance cognition and extend lifespan by reducing toxic Aβ levels. Administration of fluorescently labeled CP-2-LPs to young AD mice enables precise diagnosis, underscoring their value for early detection and targeted therapy. AbstractEarly detection and treatment are crucial for Alzheimer's disease (AD) management. Current diagnostic and therapeutic methods focus on late-stage amyloid fibrils and plaques, overlooking toxic soluble amyloid β oligomers (AβOs) accumulating early in AD. A multifunctional liposome-based platform is designed for early diagnosis and therapy of AD, leveraging a novel self-assembled cyclicd,l- α-peptide (CP-2) that selectively targets A βOs. BiocompatibleCP-2 conjugated liposomes (CP-2-LPs) effectively disrupt A β aggregation and mitigate Aβ-mediated toxicity in human neuroblastoma cells. In transgenicCaenorhabditis elegans AD models, CP-2-LPs significantly outperformed freeCP-2 by improving cognitive and behavioral functions, extending lifespan, and reducing toxic A βO levels. Intravenous injection of fluorescently labeled CP-2-LPs reveals effective blood-brain barrier penetration, with significantly higher brain fluorescence in transgenic mice than WT, enabling precise diagnosis. These findings underscore CP-2-LP...

Source: Small - March 10, 2024 Category: Nanotechnology Authors: Sudipta Senapati, Kuldeep Tripathi, Khadeja Awad, Shai Rahimipour Tags: Research Article Source Type: research